SCHEMBL3419936

SCHEMBL3419936

O=[N+]([O-])c1ccc(C2(C(O)c3cc([N+](=O)[O-])ccc3C3(CI)CCC3)CCC2)cc1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ KMT2A Q03164 4/20 0.31
▸ MEN1 O00255 3/20 0.31
▸ CYP1A2 P05177 2/20 0.31
▸ CYP2C19 P33261 2/20 0.31
▸ NPSR1 Q6W5P4 2/20 0.31
▸ LMNA P02545 2/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ HTR1E P28566 1/20 0.31
▸ S1PR3 Q99500 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ CRHBP P24387 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3229047 0.75 NPC1 (0.40) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL3237033 0.66 TSHR (0.44) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL28662620 0.61 NPC1 (0.46) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL1769433 0.60 TSHR (0.47) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL3220574 0.60 CA12 (0.39) ALDH1A1KMT2AMEN1CYP1A2CYP2C19
SCHEMBL9110057 0.60 HSD17B10 (0.48) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL17109519 0.58 ALDH1A1 (0.47) ALDH1A1LMNAMAPT
SCHEMBL3224174 0.58 NPSR1 (0.55) ALDH1A1KMT2AMEN1CYP1A2CYP2C19
SCHEMBL2817503 0.57 MAOA (0.52) ALDH1A1TSHR
Hydrochloric Acid SCHEMBL20899371 0.57 ALDH1A1 (0.45) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS GATAD2B, GATAD2A, RUNX1 NPC1 3887/4885RAB9A 2789/4885ALDH1A1 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback